Physician profile
Kerry Keldon Mackey
NPI 1417599580
$8,178.69
in general payments reported to CMS, 2019-2025
19 companies · $6,621 in 2025
The $6,621 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.62 · 2021: $268 · 2022: $377 · 2023: $731 · 2024: $170 · 2025: $6,621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,300 · Food and Beverage: $1,222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,300.00 |
| Food and Beverage | $1,221.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,858.05 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $207.55 | 2022-2023 | Rexulti, Abilify Mycite |
| Supernus Pharmaceuticals, INC. | $195.95 | 2021-2023 | Qelbree |
| Axsome Therapeutics, INC. | $125.30 | 2024-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $116.13 | 2022-2023 | |
| Corium, LLC | $116.12 | 2022-2024 | Azstarys |
| Lundbeck LLC | $100.62 | 2022-2024 | Rexulti |
| Tris Pharma INC | $81.10 | 2022-2023 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $62.98 | 2022-2023 | Spravato |
| Alkermes, INC. | $46.52 | 2023 | Lybalvi, Aristada |
| Vanda Pharmaceuticals INC. | $43.32 | 2023-2024 | Fanapt, Hetlioz |
| Neos Therapeutics, LP | $41.89 | 2019-2023 | Adzenys Xr-Odt |
| Sunovion Pharmaceuticals INC. | $41.40 | 2022 | |
| Neurocrine Biosciences, INC. | $39.63 | 2022-2024 | Ingrezza |
| Alexion Pharmaceuticals, INC. | $38.78 | 2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $20.88 | 2023 | Xelstrym |
| Teva Pharmaceuticals USA, INC. | $17.23 | 2024 | Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $13.53 | 2023 | Trintellix |
| Ironshore Pharmaceuticals INC. | $11.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerry Mackey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.